一分钟看懂
这是一项关于肺癌的II 期研究，登记的药物或干预包括18F-FDG；[18F]F-PDL1-3，当前状态为招募中。登记地点显示中国北京有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
18F-FDG；[18F]F-PDL1-3 · II 期
登记条件中文摘要
年龄范围：18岁及以上
登记的基本范围为不限性别，年龄18岁及以上；以下仅摘录7项专业入选条件，需结合英文原文并由研究团队确认。
登记记录列出6项主要排除条件，具体医学含义需结合英文原文并由研究团队确认。
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Beijing Cancer hospital · 北京
入选条件原文摘录
以下为摘录，请打开原始登记查看完整入排标准。
- 1. Age \>18 years old, ECOG score 0 or 1;
- 2. subjects with pathologically confirmed solid tumors (lung cancer, cervical cancer, melanoma, breast cancer, gastrointestinal tumor, etc.), recent recurrence or suspected recurrence of previous solid tumors;
- 3. There was at least one measurable target lesion according to RECIST1.1 criteria;
- 4. Predicted survival time ≥12 weeks;
- 5. Blood routine, liver and kidney function meet the following standards: see the study protocol for specific requirements;
- 6. Women must be using an effective contraceptive method (effective contraception means sterilization, intrauterine hormonal devices, condoms, contraceptives/pills, abstinence, or partner's removal of the vas deferentia) during the study and for 6 months after the study; Men should consent to subjects who must use contraception during the study period and for 6 months after the end of the study period;
- 7. Subjects can fully understand and voluntarily participate in this experiment, and sign an informed consent. Compliance was good.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07848243；登记信息更新于 2026-09-29；本站同步于 2026-10-08。